Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļRAPP
āļāļ·āđāļāļāļĢāļīāļĐāļąāļRapport Therapeutics Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 07, 2024
āļāļĩāļāļĩāđāļCeesay (Abraham N)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ69
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJun 07
āļāļĩāđāļāļĒāļđāđ99 High Street
āđāļĄāļ·āļāļBOSTON
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02110
āđāļāļĢāļĻāļąāļāļāđ18573218020
āđāļ§āđāļāđāļāļāđhttps://www.rapportrx.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļRAPP
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 07, 2024
āļāļĩāļāļĩāđāļCeesay (Abraham N)
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. Steven M. (Steve) Paul, M.D.
Dr. Steven M. (Steve) Paul, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
Mr. David Bredt, M.D., Ph.D.
Mr. David Bredt, M.D., Ph.D.
Chief Scientific Officer
Ms. Cheryl Gault
Chief Operating Officer
Dr. Jeffrey Sevigny, M.D.
Dr. Jeffrey Sevigny, M.D.
Chief Medical Officer
Mr. Troy A. Ignelzi
Chief Financial Officer
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Independent Director
Dr. Swamy Yeleswaram, Ph.D.
Dr. Swamy Yeleswaram, Ph.D.
Chief Development Officer
Chief Development Officer
Dr. James I. Healy, M.D., Ph.D.
Dr. James I. Healy, M.D., Ph.D.
Independent Director
Mr. Reid Huber, Ph.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. Steven M. (Steve) Paul, M.D.
Dr. Steven M. (Steve) Paul, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
Mr. David Bredt, M.D., Ph.D.
Mr. David Bredt, M.D., Ph.D.
Chief Scientific Officer
Ms. Cheryl Gault
Chief Operating Officer
Dr. Jeffrey Sevigny, M.D.
Dr. Jeffrey Sevigny, M.D.
Chief Medical Officer
Mr. Troy A. Ignelzi
Chief Financial Officer